Forest Hills, NY, United States of America

Tony Taldone

USPTO Granted Patents = 19 (Patent Applications = 4)

CIPO Patents = 8 (Patent Applications = 2)

EPO Patents = 11 (Patent Applications = 8)

Average Co-Inventor Count = 4.3

ph-index = 6

Forward Citations = 119(Granted Patents)

Location History:

New York, NY (US) (2016 - 2017)
Forest Hills, NY (US) (2018 - 2023)

Company Filing History:

11 out of 559

Memorial Sloan Kettering Cancer Center

patents

8 out of 512

Sloan-kettering Institute for Cancer Research

where one patent can have more than one assignee

Years Active: 2016-2023

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11607465 - Uses of labeled HSP90 inhibitors (2023-03-21),

2. 11267816 - Selective Grp94 inhibitors and uses thereof (2022-03-08),

3. 10793570 - Methods and reagents for radiolabeling (2020-10-06),

4. 10758538 - Heat shock protein binding compounds, compositions, and methods for making and using same (2020-09-01),

5. 10647683 - Hsp70 modulators and methods for making and using the same (2020-05-12),

6. 10421758 - Selective Grp94 inhibitors and uses thereof (2019-09-24),

7. 10329293 - Methods and reagents for radiolabeling (2019-06-25),

8. 10172863 - Purine derivatives useful as HSP90 inhibitors (2019-01-08),

9. 10160729 - Hsp70 modulators and methods for making and using the same (2018-12-25),

10. 10064867 - Hsp90 inhibitors (2018-09-04),

11. 10052325 - Heat shock protein binding compounds, compositions, and methods for making and using same (2018-08-21),

12. 9994573 - Methods and reagents for radiolabeling (2018-06-12),

13. 9926321 - Hsp90 inhibitors (2018-03-27),

14. 9878987 - HSP70 modulators and methods for making and using the same (2018-01-30),

15. 9567318 - Substituted pyrimidine compounds and uses thereof (2017-02-14),

Title: The Innovative Contributions of Tony Taldone in Cancer Research

Introduction

Tony Taldone is an accomplished inventor based in Forest Hills, NY, noted for his significant contributions to cancer treatment through innovative inventions. With a remarkable portfolio of 19 patents, he has made strides in the development of targeted therapies that aim to improve patient outcomes.

Latest Patents

Two of Taldone's latest patents highlight his dedication to advancing cancer treatment. The first patent, "Uses of labeled HSP90 inhibitors," focuses on various methods of utilizing labeled HSP90 inhibitors to enhance treatment for cancer patients. This invention includes both ex vivo and in vivo methods for determining a tumor's likely response to therapy with HSP90 inhibitors. The second patent, "Selective Grp94 inhibitors and uses thereof," relates to novel selective Grp94 inhibitors. This patent encompasses compositions consisting of effective amounts of these compounds and outlines methods for treating or preventing conditions such as cancer by administering these compounds to animals in need.

Career Highlights

Tony Taldone has showcased his expertise while working at prestigious institutions, including Memorial Sloan Kettering Cancer Center and the Sloan Kettering Institute for Cancer Research. His profound knowledge and innovative approach have made him a key player in the field of cancer research and treatment.

Collaborations

Throughout his career, Taldone has collaborated with notable professionals in the field, such as Gabriela Chiosis and Stefan O. Ochiana. These collaborations have fostered an environment of innovation and have contributed to significant advancements in cancer therapy.

Conclusion

Tony Taldone's work exemplifies the impact of innovation in medicine, particularly in the fight against cancer. His patents reflect not only his inventiveness but also his commitment to improving patient care through targeted therapies. With his ongoing contributions, Taldone continues to inspire advancements in cancer research and treatment.

This text is generated by artificial intelligence and may not be accurate.